DE69530389D1 - Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen - Google Patents

Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Info

Publication number
DE69530389D1
DE69530389D1 DE69530389T DE69530389T DE69530389D1 DE 69530389 D1 DE69530389 D1 DE 69530389D1 DE 69530389 T DE69530389 T DE 69530389T DE 69530389 T DE69530389 T DE 69530389T DE 69530389 D1 DE69530389 D1 DE 69530389D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
compositions
neuroprotective pharmaceutical
effective
dexanabinol derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69530389T
Other languages
English (en)
Other versions
DE69530389T2 (de
Inventor
Raphael Mechoulam
Emil Pop
Mordechai Sokolovsky
Yoel Kloog
Anat Biegon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Pharmos Corp
Original Assignee
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Yissum Research Development Co of Hebrew University of Jerusalem, Pharmos Corp filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of DE69530389D1 publication Critical patent/DE69530389D1/de
Publication of DE69530389T2 publication Critical patent/DE69530389T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69530389T 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen Expired - Fee Related DE69530389T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US192886 1994-02-07
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals
PCT/US1995/001470 WO1995020958A1 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69530389D1 true DE69530389D1 (de) 2003-05-22
DE69530389T2 DE69530389T2 (de) 2004-03-25

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530389T Expired - Fee Related DE69530389T2 (de) 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (1) US5521215A (de)
EP (1) EP0765160B1 (de)
JP (1) JPH09511493A (de)
AT (1) ATE237324T1 (de)
AU (1) AU690221B2 (de)
CA (1) CA2183466A1 (de)
DE (1) DE69530389T2 (de)
IL (1) IL112572A0 (de)
SG (1) SG49625A1 (de)
WO (1) WO1995020958A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
WO1998050027A1 (en) * 1997-05-07 1998-11-12 Unimed Pharmaceutical, Inc. Method of improving disturbed behavior and elevating mood in humans
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
WO1999025350A1 (en) * 1997-11-14 1999-05-27 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
EP1071419B1 (de) 1998-04-21 2007-07-25 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cannabinoiden als antioxidantien und neuroschützende mittel
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
EP1785417A3 (de) * 2000-06-22 2007-08-01 Pharmos Corporation Neuartige nicht-psychotrope Cannabinoide
AU783522B2 (en) * 2000-06-22 2005-11-03 Pharmos Corporation Novel non-psychotropic cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2002058636A2 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
JP2005503998A (ja) 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット 受容体選択性のカンナビミメティックアミノアルキルインドール
US7705039B2 (en) * 2001-04-06 2010-04-27 The Board Of Trustees Of The University Of Illinois Method for treating sleep apnea
AU2002320430A1 (en) * 2001-07-13 2003-01-29 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
CN1589269A (zh) * 2001-10-26 2005-03-02 康涅狄格大学 杂1,2－二氢化茚:一类新型有效的大麻配体
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
AU2003256059A1 (en) * 2002-09-05 2004-03-29 Pharmos Corporation Non-psychotropic cannabinoids for prevention of cognitive impairment
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004050011A2 (en) * 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
NZ567029A (en) 2005-09-29 2011-09-30 Amr Technology Inc Process for production of delta-9- tetrahydrocannabinol
CA2694325C (en) * 2007-07-30 2015-09-22 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
EP3654942A1 (de) 2017-07-20 2020-05-27 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pharmazeutische filmzusammensetzungen zur verabreichung von lipophilen verbindungen in die haut und / oder über die haut
WO2019049145A1 (en) 2017-09-11 2019-03-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT
US20200345656A1 (en) 2017-11-29 2020-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
EP3873436A1 (de) 2018-11-04 2021-09-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Oral verabreichbare cannabinoide enthaltende zusammensetzungen und verfahren
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2183466A1 (en) 1995-08-10
SG49625A1 (en) 1998-06-15
EP0765160A4 (de) 1997-04-09
AU1743395A (en) 1995-08-21
EP0765160B1 (de) 2003-04-16
AU690221B2 (en) 1998-04-23
ATE237324T1 (de) 2003-05-15
DE69530389T2 (de) 2004-03-25
WO1995020958A1 (en) 1995-08-10
IL112572A0 (en) 1995-05-26
US5521215A (en) 1996-05-28
JPH09511493A (ja) 1997-11-18
EP0765160A1 (de) 1997-04-02

Similar Documents

Publication Publication Date Title
ATE237324T1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP1299374A4 (de) Neue nicht psychotropische cannabinoide
BG101118A (en) Therapeutical compounds
DE69636308D1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
SE9604786D0 (sv) New compounds
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
DE69531098D1 (de) Piperidine und pyrrolidine
CA2243404A1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU2030497A (en) Propynyl or dienyl biaromatic compounds
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
HK1050203A1 (en) Novel fusidic acid derivatives.
EP1785417A3 (de) Neuartige nicht-psychotrope Cannabinoide
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
UA31266A (uk) Лікувальний засіб "дінальгін"
GR980100028A (el) Φαρμακευτικα προιοντα για τοπικη χρηση που περιεχουν φλουκοναζολη σε συγκεντρωσεις μεταξυ 0,2% και 5%

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee